NCT06151223Recruiting
A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
Source: ClinicalTrials.gov · Last updated 10 Mar 2026
Brief summary (registry, in English)
This study aims to facilitate discovery and validation of tests for early detection in subjects at high risk for pancreatic ductal adenocarcinoma (PDAC) and to facilitate the use of state-of-the-art machine learning-based algorithms that utilize databases and images with the purpose of identifying early stages of pancreatic cancer, as well as people at high-risk.The study also aims to provide a platform for development of an interventional protocol for early detection of PDAC.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 5000 (estimated)
- First submitted
- 21 Nov 2023
- Start date
- 13 Jul 2021
- Primary completion date
- 31 Jul 2031
- Lead sponsor
- Mayo Clinic
- Diseases
- Pancreatic cancer
- NCT number
- NCT06151223
What you commit to
- Study type: Observational
- Planned participants: 5000
- From 13 Jul 2021 to the primary completion date, 31 Jul 2031
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Individual who has a personal history of pancreatic ductal adenocarcinoma (PDAC)
- History of total pancreatectomy
Who the study is looking for
- Age ≥ 18 year
- Able to provide written informed consent
- Meets criteria as a High-Risk Individual as defined by protocol
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic in Rochester Coordinator of this site? Confirm its status | Rochester | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.